Question 1

Which Alzheimer's targets does NoorGenX cover?

Accepted Answer

NoorGenX Alzheimer's covers the major druggable axes: BACE1 (β-secretase, amyloid-β production), GSK-3β and MAPT/tau (neurofibrillary tangles), ACHE (acetylcholinesterase, cholinergic symptomatic), APOE4 (strongest genetic risk factor), and neuroinflammation (TREM2, microglia). Each target includes BDE-MANGO GO/WATCH/NO-GO drug repurposing decisions with a blood-brain-barrier penetrance check.

Question 2

Why does NoorGenX check the blood-brain barrier for every Alzheimer's candidate?

Accepted Answer

Alzheimer's is a central-nervous-system disease, so a drug must cross the blood-brain barrier (BBB) to reach its target. NoorGenX runs a CNS_BARRIER_CHECK on every candidate — flagging molecular weight ≤ 450 Da, topological polar surface area ≤ 90 Å², hydrogen-bond donors ≤ 3, and predicted BBB permeability. Candidates that fail the CNS filter are demoted regardless of on-target potency.

Question 3

What is BACE1 and why is it a key Alzheimer's target?

Accepted Answer

BACE1 (β-site amyloid precursor protein cleaving enzyme 1, β-secretase) makes the first cut in the amyloid precursor protein that leads to amyloid-β peptide — the plaque-forming species in Alzheimer's. NoorGenX BDE-MANGO scores BACE1 inhibitors against ChEMBL bioactivity data and models their 3D binding to the BACE1 catalytic pocket using the PDB 4B05 structure inside the NVIDIA BioNeMo viewer.

Question 4

Is NoorGenX Alzheimer's free to use?

Accepted Answer

Yes. All patient- and caregiver-facing resources including drug information, target analysis, clinical trial matching, and educational content are completely free. NoorGenX operates on a licensing model for pharmaceutical partners, not patient fees. No Disease Left Behind.